We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

BioXcel Begins Strategic Collaboration with Alnylam

BioXcel Begins Strategic Collaboration with Alnylam

BioXcel Begins Strategic Collaboration with Alnylam

BioXcel Begins Strategic Collaboration with Alnylam

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioXcel Begins Strategic Collaboration with Alnylam "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioXcel Corporation has announced the initiation of a strategic collaboration with Alnylam Pharmaceuticals to discover novel RNA interference (RNAi) therapeutic products. Alnylam is focused on developing and commercializing RNAi therapeutics – a new class of innovative medicines – with a focus on genetically defined targets for the treatment of serious diseases.

Alnylam will leverage BioXcel’s Big Data Innovation Lab* (BDI-Lab) – by integrating the product discovery engine that will apply big data algorithms, recursive mapping and network pharmacology in conjunction with therapeutic expertise to build product blueprints for novel RNAi therapeutic products with a high probability of clinical and commercial success.

“We are pleased to join forces with Alnylam and leverage two disruptive platforms to create a portfolio of RNAi products for rare and common diseases. As we continue to collaborate with leading innovative biopharmaceutical companies across the spectrum of therapeutic modalities including RNAi, mRNA, gene therapy, gene editing, amino acid and cell based therapies, we hope to impact patients’ lives by providing novel treatment options,” said Krishnan Nandabalan, Ph.D., BioXcel’s President and Chief Scientific Officer.

Under the terms of the agreement, BioXcel will be eligible to receive upfront and development milestone related payments from Alnylam. Financial terms of the agreement were not disclosed.

*Big Data Innovation Lab (BDI-Lab)

BDI-Lab is a first-of-its-kind ecosystem that identifies novel therapeutic candidates with a high probability of clinical and commercial success.  The Lab supports any therapeutic area and modality ranging from small molecules to biologics, cellular- and nucleic acid-based therapies and is accessible to the biopharmaceutical industry through strategic partnerships.

The Lab has been built on decades of research and algorithm-based analytics with its core consisting of PharmGPS®, a real-time, predictive, cognitive intelligence platform for designing, strategizing, developing, and commercializing the next breakthrough treatments; a large Center of multi-disciplinary teams with deep domain expertise, to unlock the therapeutic value of technology platforms and pipeline assets; and a highly experienced and therapeutically aligned drug development team whose expertise spans all stages of development across any major therapeutic area or rare disease, to generate drug candidates.